Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Trading 11-05 11:23:26 EST

7.31

-0.66

-8.28%

High7.95	Low7.13	Vol364.75K
Open7.85	D1 Closing7.97	Amplitude10.29%
Mkt Cap607.31M	Tradable Cap514.09M	Total Shares83.08M
T/O2.70M	T/O Rate0.52%	Tradable Shares70.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":7.31,"timestamp":1793895806391,"preClose":7.97,"halted":0,"volume":364751,"delay":0,"changeRate":-0.08281053952321206,"floatShares":70327041,"shares":83079200,"eps":-0.8667,"marketStatus":"Trading","change":-0.66,"latestTime":"11-05 11:23:26 EST","open":7.85,"high":7.95,"low":7.13,"amount":2701965.4720485997,"amplitude":0.102886,"askPrice":7.32,"askSize":200,"bidPrice":7.29,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-0.8667,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793912400000},"marketStatusCode":2,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":7.97,"preHourTrading":{"tag":"盘前","latestPrice":7.84,"preClose":7.97,"latestTime":"09:29 EST","volume":9852,"amount":78565.3493568,"timestamp":1793888999999,"change":-0.13,"changeRate":-0.016311,"amplitude":0.11276},"postHourTrading":{"tag":"盘后","latestPrice":7.97,"preClose":7.97,"latestTime":"19:30 EST","volume":18631,"amount":148488.92,"timestamp":1793838603838,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.992668,"impliedVol":1.9203,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/IMMX/tweets","defaultTab":"tweets","newsList":[{"id":"2680057414","title":"Immix Biopharma to Present NXC-201 Trial Data from 45 Patients at ASH 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057414","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680057414?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:17","pubTimestamp":1793801871,"startTime":"0","endTime":"0","summary":"Immix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026Immix Biopharma will present interim NXC-201 trial results at the American Society of Hematology meeting on December 14, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL12k8Jd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","NDAQ","IE00BQXX3F31.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","IMMX","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680057195","title":"Immix Biopharma’s Nxc-201 Nexicart-2 Interim Clinical Trial Results Selected for Oral Presentation at Ash 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680057195?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:15","pubTimestamp":1793801700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA2JQDND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679409390","title":"Immix Biopharma price target lowered to $23 from $26 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2679409390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679409390?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:40","pubTimestamp":1793274030,"startTime":"0","endTime":"0","summary":"Mizuho lowered the firm’s price target on Immix Biopharma (IMMX) to $23 from $26 and keeps an Outperform rating on the shares. Published first on T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-price-target-lowered-to-23-from-26-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-price-target-lowered-to-23-from-26-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707456","title":"Immix Biopharma to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707456","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707456?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:45","pubTimestamp":1791204324,"startTime":"0","endTime":"0","summary":"Immix Biopharma to present at J.P. Morgan Healthcare ConferenceImmix Biopharma will present at the 45th Annual J.P. Morgan Healthcare Conference on Jan. 11-14, 2027, in San Francisco.Disclaimer:This n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL7wZyxW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BQXX3F31.USD","LU0314104364.USD","BCDF","LU2210150020.SGD","IE00BGHQF748.EUR","BK4588","SG9999014039.USD","BK4139","BK4585","BK4112","SG9999014013.SGD","NDAQ","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672780320","title":"Immix Biopharma Closes $125 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2672780320","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672780320?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:36","pubTimestamp":1790804218,"startTime":"0","endTime":"0","summary":"Immix Biopharma  closed its previously announced underwritten offering of 11.4 million common shares at $11 each, raising net proceeds of about $117.1 million, the company said Wednesday.The company plans to use the proceeds to fund development of NXC-201, working capital and general corporate purposes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672787277","title":"Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672787277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672787277?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:15","pubTimestamp":1790802900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA6X8R8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279309","title":"US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279309","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671279309?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:35","pubTimestamp":1790753728,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDBSept 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Alnylam","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCL","AEE","AJG","EGGY","HNGE","MRSH","BBUC","LITE","IMMX","MSFD","ANNX","CSCO","MRNX","KMX","HUN","ANAB","MRNA","IOND","HAWK","MSFT","CCL","AMPL","MSFO","CIEN","FSLR","GNRC","MDB","DOW","ANET","ACHV","GLW","COHR","SKYY","BRO","BCRX","CE","LW","SPRX","CSCS","EMN","CVNA","JAZZ","AIR","ALNY","GSHD","GPK","DYN","GAMR","CC","EFIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222142","title":"Immix Biopharma, Inc. : Needham Raises Target Price to $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671222142?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:49","pubTimestamp":1790740179,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45L228:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671624609","title":"Immix Biopharma is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2671624609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671624609?lang=en_us&edition=fundamental","pubTime":"2026-09-30 01:04","pubTimestamp":1790701440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671452902","title":"Immix Biopharma price target raised to $30 from $27 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2671452902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671452902?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:45","pubTimestamp":1790696719,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Immix Biopharma (IMMX) to $30 from $27 and keeps a Buy rating on the shares. Following interim data, the fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-price-target-raised-to-30-from-27-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-price-target-raised-to-30-from-27-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671821641","title":"Immix Biopharma prices 11.36M share registered offering at $11.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2671821641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671821641?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:15","pubTimestamp":1790680527,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-prices-11-36m-share-registered-offering-at-11-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-prices-11-36m-share-registered-offering-at-11-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671216392","title":"Immix Biopharma Prices 11,363,637-Share Offering at USD 11.00 Per Share for USD 125 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216392","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671216392?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:05","pubTimestamp":1790679920,"startTime":"0","endTime":"0","summary":"Immix Biopharma prices 11,363,637-share offering at USD 11.00 per share for USD 125 million gross proceedsImmix Biopharma priced an underwritten offering of 11,363,637 common shares at USD 11.00 each.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL8Jsk6f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IMMX","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","BCDF","BK4139","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671216301","title":"Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216301","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671216301?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:05","pubTimestamp":1790679907,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671327216","title":"Immix Biopharma, - Prices 11,363,637 Shares at $11 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2671327216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671327216?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:05","pubTimestamp":1790679900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA7TXDYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671321630","title":"Immix Biopharma, - Net Proceeds to Fund Nxc-201 Development, Working Capital, Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2671321630","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671321630?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:05","pubTimestamp":1790679900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA7TXDYL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671099215","title":"Immix Biopharma Says Nexicart-2 Interim Data Show 89% Complete Response Rate for NXC-201 in Relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671099215","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671099215?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:01","pubTimestamp":1790679695,"startTime":"0","endTime":"0","summary":"Immix Biopharma says NEXICART-2 interim data show 89% complete response rate for NXC-201 in relapsed/refractory AL amyloidosisImmix Biopharma reported interim trial results for NXC-201 in relapsed or ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL3l8Syt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IMMX","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4585","BK4139","LU0314104364.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4112","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","NDAQ","BK4588","SG9999014021.USD","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215029","title":"Immix Biopharma, - Nexicart-2 Final Readout and Bla Submission Planned for Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671215029?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679650,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L02E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671157342","title":"Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All Nexicart-2 Patients, with Mrd-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671157342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671157342?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679650,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671074215","title":"Immix Biopharma, - 100% of New Nexicart-2 Patients in Complete Response or Mrd-Negative","url":"https://stock-news.laohu8.com/highlight/detail?id=2671074215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671074215?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679650,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L02E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667960208","title":"Immix Biopharma, Inc. : Mizuho Raises Target Price to $26 from $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2667960208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667960208?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:39","pubTimestamp":1789555147,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4570M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.2132},{"period":"3month","weight":-0.2078},{"period":"6month","weight":-0.1826},{"period":"1year","weight":1.3934},{"period":"ytd","weight":0.5239}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.025442},{"month":5,"riseRate":0.6,"avgChangeRate":0.091547},{"month":6,"riseRate":0.6,"avgChangeRate":0.103039},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025858},{"month":8,"riseRate":0.4,"avgChangeRate":0.053526},{"month":9,"riseRate":0.2,"avgChangeRate":-0.037738},{"month":10,"riseRate":0.6,"avgChangeRate":0.084778},{"month":11,"riseRate":1,"avgChangeRate":0.219307},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction